Related Experiment Videos

Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target

Olga A Timofeeva1, Vadim Gaponenko, Stephen J Lockett

  • 1Laboratory of Comparative Carcinogenesis, National Cancer Institute, NCI-Frederick, Maryland 21702, USA.

ACS Chemical Biology
|December 25, 2007
PubMed

Insights

Researchers developed novel STAT3 inhibitors targeting cancer cell proliferation. These compounds specifically bind to STAT3, inducing apoptosis in cancer cells while sparing normal cells, offering a new therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Signal transducer and activator of transcription 3 (STAT3) activation is common in many cancers.
  • Activated STAT3 promotes tumor growth, survival, angiogenesis, invasion, and migration.
  • The STAT3 N-domain is crucial for protein interactions mediating cellular responses.

Purpose of the Study:

  • To design and synthesize STAT3 N-domain inhibitors.
  • To evaluate the specificity and efficacy of these inhibitors.
  • To investigate the mechanism of STAT3 inhibition and its effect on cancer cells.

Main Methods:

  • NMR studies of STAT4 helix analogs binding to the STAT3 N-domain.
  • Rational design of STAT3 helix 2 analogs based on structural data.
  • FRET analysis to determine binding specificity to STAT3 vs. STAT1.
  • Assessment of apoptosis induction and mitochondrial potential changes in cancer cells.

Main Results:

  • Synthetic STAT3 helix 2 analogs specifically bind to STAT3, not STAT1.
  • These cell-permeable derivatives induce apoptosis in breast cancer cells.
  • Inhibitors do not affect normal breast cells or STAT3-deficient fibroblasts.
  • Compounds alter mitochondrial potential, leading to cancer cell death.

Conclusions:

  • Novel STAT3 N-domain inhibitors show high specificity and potency against cancer cells.
  • These compounds represent promising drug candidates for cancer therapy.
  • The developed inhibitors serve as valuable tools for studying STAT transcription factor mechanisms.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...